Population Pharmacokinetics of Tapentadol Immediate Release (IR) in Healthy Subjects and Patients with Moderate or Severe PainXU, Xu Steven; SMIT, Johan W; LIN, Rachel et al.Clinical pharmacokinetics. 2010, Vol 49, Num 10, pp 671-682, issn 0312-5963, 12 p.Article

NIFEDIPINE PREPARATIONS ON THE BELGIAN MARKET: A COMPARATIVE STUDYDE BRAEKELEER, K; FIERENS, C; CORTHOUT, J et al.Journal de pharmacie de Belgique. 2009, Num 4, pp 141-146, issn 0047-2166, 6 p.Article

Oxymorphone par voie orale = Oral oxymorphoneThe Medical letter on drugs and therapeutics (Edition française). 2007, Vol 29, Num 3, pp 11-12, issn 0253-8512, 2 p.Article

Once- versus twice-daily venlafaxine therapy in major depression : A randomized, double-blind studyAMSTERDAM, J. D; HOOPER, M. B; AMCHIN, J et al.The Journal of clinical psychiatry. 1998, Vol 59, Num 5, pp 236-240, issn 0160-6689Article

En bref: Oxycodone à libération immédiate = In brief: immediate-release oxycodone (Oxecta) for painThe Medical letter on drugs and therapeutics (Edition française). 2012, Vol 34, Num 7, issn 0253-8512, p. 25Article

New formulations of stimulants for attention-deficit hyperactivity disorder: Therapeutic potentialCONNOR, Daniel F; STEINGARD, Ronald J.CNS drugs. 2004, Vol 18, Num 14, pp 1011-1030, issn 1172-7047, 20 p.Article

A novel electrostatic dry powder coating process for pharmaceutical dosage forms: Immediate release coatings for tabletsMINGXI QIAO; LIQIANG ZHANG; YINGLIANG MA et al.European journal of pharmaceutics and biopharmaceutics. 2010, Vol 76, Num 2, pp 304-310, issn 0939-6411, 7 p.Article

Salting-out taste-masking system generates lag time with subsequent immediate releaseYOSHIDA, T; TASAKI, H; MAEDA, A et al.International journal of pharmaceutics (Print). 2009, Vol 365, Num 1-2, pp 81-88, issn 0378-5173, 8 p.Article

Biowaivers for oral immediate-release products: Implications of linear pharmacokineticsFAASSEN, Fried; VROMANS, Herman.Clinical pharmacokinetics. 2004, Vol 43, Num 15, pp 1117-1126, issn 0312-5963, 10 p.Article

Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. EditorialLESSER, Ronald P; KRAUSS, Gregory; WILDER, B. J et al.Neurology. 2001, Vol 57, Num 4, pp 571-573, issn 0028-3878, 11 p.Article

Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamilKRECIC-SHEPARD, Mary Ellen; BARNAS, Crissy R; SLIMKO, Jill et al.Clinical pharmacology and therapeutics. 2000, Vol 68, Num 3, pp 286-292, issn 0009-9236Article

Clinical Efficacy and Safety of Tapentadol Immediate Release in the Postoperative SettingDANIELS, Stephen E; GOLF, Michael.Journal of the American Podiatric Medical Association (Print). 2012, Vol 102, Num 2, pp 139-148, issn 8750-7315, 10 p.Article

Tapentadol Immediate Release: A Review of its Use in the Treatment of Moderate to Severe Acute PainFRAMPTON, James E.Drugs (Basel). 2010, Vol 70, Num 13, pp 1719-1743, issn 0012-6667, 25 p.Article

Effects of physicochemical properties of salting-out layer components on drug releaseTASAKI, Hiroaki; YOSHIDA, Takayuki; MAEDA, Atsushi et al.International journal of pharmaceutics (Print). 2009, Vol 376, Num 1-2, pp 13-21, issn 0378-5173, 9 p.Article

The relative densities of pharmaceutical powders, blends, dry granulations, and immediate-release tabletsHANCOCK, Bruno C; COLVIN, Joshua T; MULLARNEY, Matthew P et al.Pharmaceutical technology. 2003, Vol 27, Num 4, pp 64-80, issn 0147-8087, 9 p.Article

Tablet formulation for the fast and sustained-release of flavonoids : naringin and naringeninLAURO, M. R; TORRE, M. L; MAGGI, L et al.STP pharma sciences. 2001, Vol 11, Num 4, pp 265-269, issn 1157-1489Article

Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepineBIALER, M; ARCAVI, L; SUSSAN, S et al.Epilepsy research. 1998, Vol 32, Num 3, pp 371-378, issn 0920-1211Article

The new era of biotech insulin analogues : Insulin: action and secretionBRANGE, J.Diabetologia (Berlin). 1997, Vol 40, pp S48-S53, issn 0012-186X, SUP2Conference Paper

Absolute bioavaibility of oral immediate and slow release fluphenazine in healthy volunteersKOYTCHEV, R; ALKEN, R.-G; MCKAY, G et al.European journal of clinical pharmacology. 1996, Vol 51, Num 2, pp 182-187, issn 0031-6970, 5 p.Article

In vivo/in vitro correlations for four differently dissolving ketorolac tabletsGORDON, M. S; CHOWHAN, Z.Biopharmaceutics & drug disposition. 1996, Vol 17, Num 6, pp 481-492, issn 0142-2782Article

Evaluation of the Abuse Potential of Extended Release Hydromorphone Versus Immediate Release HydromorphoneSHRAM, Megan J; SATHYAN, Gayatri; KHANNA, Sarita et al.Journal of clinical psychopharmacology. 2010, Vol 30, Num 1, pp 25-33, issn 0271-0749, 9 p.Article

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patientsLESEM, Michael D; ZAJECKA, John M; SWIFT, Rachel H et al.The Journal of clinical psychiatry. 2001, Vol 62, Num 1, pp 12-18, issn 0160-6689Article

Formulation, in vitro and in vivo evaluation of fast release double layer theophylline suppositoriesSOLIMAN, Safaa A; GADALLA, Mohamed A. F; NAGGAR, Viviane F et al.Acta pharmaceutica (Zagreb). 2000, Vol 50, Num 4, pp 315-328, issn 1330-0075Article

Cefaclor revisitedMEYERS, B. R.Clinical therapeutics. 2000, Vol 22, Num 2, pp 154-166, issn 0149-2918Article

Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutyninGUPTA, S. K; SATHYAN, G.Journal of clinical pharmacology. 1999, Vol 39, Num 3, pp 289-296, issn 0091-2700Conference Paper